结肠癌细胞多药耐药模型LoVo/Adr的建立及其耐药相关基因的表达

被引:14
作者
马强
张振书
王群英
钟世顺
李恕军
赖卓胜
机构
[1] 第一军医大学南方医院消化科
关键词
结肠癌; 多药耐药性; 耐药相关基因; 阿霉素;
D O I
暂无
中图分类号
R735.35 [];
学科分类号
摘要
目的 建立结肠癌细胞多药耐药模型LoVo/Adr并研究其耐药机制。方法 采用阿霉素浓度递增法 ,建立人结肠癌细胞多药耐药模型LoVo/Adr ,观察其生长规律 ;用MTT法鉴定耐药细胞株的耐药性 ;以流式细胞术检测其周围分布 ;用RT PCR方法检测耐药相关基因mdr1、MRP、GST π及TopoⅡmRNA水平在诱导耐药过程中的变化 ;采用免疫组化法检测P gp的表达。 结果 LoVo/Adr细胞与LoVo细胞相比 ,生长缓慢 ,倍增时间延长 ,细胞形态较不规则 ,S期细胞减少 ,而G1、G2期增多 ,P gp染色阳性。LoVo/Adr对阿霉素、长春新碱、丝裂霉素、环磷酰胺和 5 FU耐药倍数分别是 6 1倍、14倍、3倍、9倍和 1倍。亲本LoVo细胞mdr1不表达 ,随着阿霉素诱导mdr1mRNA水平逐渐增高 ,GST πmRNA在诱导初期显著增高 ,但不随着对阿霉素耐受浓度增加而升高 ;ToopⅡmRNA水平一直无显著变化 ;未测到MRP的表达。结论 耐药株LoVo/Adr是一个表达MDR表型的多药耐药模型 ,主要由mdr1和GST π基因介导耐药 ,与TopoⅡ和MRP基因无关
引用
收藏
页码:27 / 30
页数:4
相关论文
共 9 条
[1]  
Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Schneider E,Yamazaki H,Sinha BK,et al. British Journal of Cancer . 1995
[2]  
On the reaction mechanism of class Pi glutathione S-transferase. Orozco M,Vega C,Parraga A,et al. Proteins . 1997
[3]  
P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine. Ruiz Gomez MJ,Souviron A,Martinez Morillo M,et al. Journal of Physiology and Biochemistry . 2000
[4]  
Cellular mechanisms of multidrug resistance of tumor cells. Stavrovskaya AA. Biochemistry . 2000
[5]  
Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. Yang LY,Trujillo JM. Cancer Research . 1990
[6]  
P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Maraldi NM,Zini N,Santi S,et al. Biology of the Cell . 1999
[7]  
Expression of multidrug resistance-related genes (mdr1, MRP, GST-pi and DNA topoisomeraseⅡ) in urothelial cancers. Kim WJ,Kakehi Y,Wu WJ,et al. British Journal of Urology . 1996
[8]  
In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. Lorke DE,Kruger M,Buchert R,et al. The Journal of Nuclear Medicine . 2001
[9]  
Multidrug resistance and its reversal. Volm M. Anticancer Research . 1998